NCT06989437 2026-02-06
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Pfizer
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT06361888 2025-12-30
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3 Recruiting
NCT07219238 2025-10-21
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Not yet recruiting
NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
NCT05254171 2024-11-06
ASPIRE
Panbela Therapeutics, Inc.
Phase 2/3 Recruiting
NCT00113256 2024-08-02
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Astex Pharmaceuticals, Inc.
Phase 2/3 Terminated
NCT03721744 2024-04-03
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
Phase 2/3 Recruiting
NCT04083651 2021-05-07
A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 2/3 Withdrawn
NCT00561990 2015-10-15
Nimotuzumab in Adults With Pancreatic Cancer
Oncoscience AG
Phase 2/3 Completed
NCT00332280 2013-03-20
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
Auron Healthcare GmbH
Phase 2/3 Terminated